RenovoRx (RNXT) AI Stock Analysis

• Market Cap: $32.21M
• Dividend Yield: N/A
• Average Volume (3M): 79.13K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.08
• Revenue Growth: N/A
• EPS Growth: 61.43%
• Country: US
• Employees: 8
• Sector: Healthcare
• Sector Strength: 77
• Industry: Biotechnology
• EPS (TTM): -0.39
• Shares Outstanding: 36,546,753
• 10 Day Avg. Volume: 97,946
• 30 Day Avg. Volume: 79,132
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• Price to Cash Flow (P/CF): -2.60
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $3.00
• Price Target Upside: 240.91% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

RenovoRx's overall stock score reflects significant financial challenges, with persistent operational losses and negative cash flows. Technical analysis suggests ongoing bearish trends, while valuation is hampered by a negative P/E ratio and lack of dividend yield. The absence of earnings call data and corporate events further underscores the company's uncertain outlook.

Positive Factors

Clinical Trial Progress

The company is on track to complete enrollment in the 114-patient Phase 3 TIGeR-PaC study, which is crucial for advancing its treatment for pancreatic cancer.

Market Potential

With a total addressable worldwide market of approximately $740M, if successful, the company could generate significant revenues.

Revenue Generation

RenovoCath realizes first revenues, marking a significant milestone for the company.

Negative Factors

Earnings Report

RenovoRx reported 3Q24 results with a net loss of ($2.4M) and ended the period with $9.5M in cash on the balance sheet, which should provide runway into 1H25.

Financial Performance

The company reported a net loss of $0.40 per diluted share for the fourth quarter.

Shareholder Value

The current valuation is considered attractive, with a raised 12-month price target to $9.00, representing significant upside from the current share price.

RenovoRx Business Overview & Revenue Model

Company Description

RenovoRx (RNXT) is a biopharmaceutical company focused on developing targeted therapies for cancer treatment. The company is dedicated to improving patient outcomes by delivering chemotherapy directly to tumors via its proprietary RenovoTAMP (Trans-Arterial Micro-Perfusion) therapy platform. This platform is designed to enhance the efficacy of existing chemotherapeutic agents while minimizing systemic exposure and associated side effects.

How the Company Makes Money

RenovoRx generates revenue primarily through the development and commercialization of its RenovoTAMP therapy platform. The company aims to monetize its technology through licensing agreements with pharmaceutical companies and healthcare institutions. Additionally, RenovoRx seeks to establish partnerships and collaborations to further develop its therapeutic applications, which can lead to milestone payments and royalties. The company's financial strategy may also include seeking funding through public and private investments to support ongoing research and development efforts.

RenovoRx Financial Statement Overview

Summary

RenovoRx faces significant financial challenges with no revenue generation and consistent losses. The balance sheet shows some improvements in equity position, but the company remains highly dependent on external financing, posing risks to its financial stability.

Income Statement

RenovoRx has shown consistent negative net income and EBIT over the years, with no revenue generated. The company's lack of revenue growth limits its ability to improve profitability, leading to poor performance in income statement metrics.

Balance Sheet

The company has managed to reduce its liabilities over the years, resulting in a positive stockholders' equity as of the latest TTM period. However, the absence of revenue and reliance on equity financing pose risks to financial stability.

Cash Flow

Operating cash flows remain negative with no free cash flow generation, indicating a heavy reliance on financing activities to sustain operations. While financing cash flow has been positive, it highlights dependence on external funding.

Breakdown
TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
0.00	0.00	0.00	0.00	0.00	0.00
	Gross Profit
0.00	0.00	-6.00K	-9.00K	0.00	0.00
	EBIT
-10.12M	-11.40M	-9.95M	-5.67M	-3.20M	-3.90M
	EBITDA
-6.94M	-11.39M	-9.94M	-5.66M	0.00	0.00
	Net Income Common Stockholders
-9.16M	-10.23M	-9.77M	-7.10M	-4.38M	-3.78M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
2.10M	1.17M	6.44M	15.19M	1.79M	2.10M
	Total Assets
0.00	1.47M	7.26M	16.29M	1.91M	2.27M
	Total Debt
0.00	0.00	0.00	0.00	2.79M	12.39M
	Net Debt
2.10M	-1.17M	-6.44M	-15.19M	995.00K	10.29M
	Total Liabilities
0.00	4.47M	1.10M	938.00K	16.57M	13.20M
	Stockholders Equity
1.47M	-3.00M	6.16M	15.35M	-14.66M	-10.93M
Cash Flow		Free Cash Flow
-8.75M	-10.26M	-8.81M	-5.93M	-3.53M	-3.35M
	Operating Cash Flow
-8.75M	-10.26M	-8.81M	-5.92M	-3.53M	-3.35M
	Investing Cash Flow
0.00	2.03M	-2.03M	-15.00K	0.00	-1.00K
	Financing Cash Flow
15.09M	5.01M	42.00K	19.33M	3.20M	0.00

RenovoRx Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.88
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RNXT, the sentiment is Negative. The current price of 0.88 is below the 20-day moving average (MA) of 0.97, below the 50-day MA of 1.07, and below the 200-day MA of 1.13, indicating a bearish trend. The MACD of -0.02 indicates Negative momentum. The RSI at 42.43 is Neutral, neither overbought nor oversold. The STOCH value of 26.82 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for RNXT.

RenovoRx Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	48 Neutral	$6.35B	1.19	-46.87%	2.63%	17.16%	1.34%
SRZN	46 Neutral	$36.06M	―	-767.91%	―	―	0.13%
INKT	44 Neutral	$33.36M	―	78.50%	―	―	55.52%
RNXT	40 Underperform	$32.21M	―	-1192.69%	―	―	61.43%
TPST	38 Underperform	$27.93M	―	-182.35%	―	―	21.75%
ALXO	38 Underperform	$27.54M	―	-88.91%	―	―	30.37%
RNTX	26 Underperform	$36.83M	―	-82.37%	―	―	-9.30%